Evidence map›Paper›PMID 40533599›Full record

SynthesisJournal of neurology2025

A meta-analysis of survival and prognostic factors in multiple system atrophy.

Xiao Dong, Daji Chen, Linlin Wan, Linliu Peng, Zhao Chen, Riwei Ouyang, Xiafei Long, Kefang Du, Xiaokang Wu, Xinying Xiao and 4 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiao DongDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Daji ChenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Linlin WanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Linliu PengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhao ChenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Riwei OuyangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xiafei LongDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Kefang DuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xiaokang WuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xinying XiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Ruqing HeDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Rong QiuSchool of Computer Science and Engineering, Central South University, Changsha, 410083, China.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Hong JiangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China. jianghong73868@csu.edu.cn.ORCID http://orcid.org/0000-0003-2812-4120

Funding

Central South University Research Programme of Advanced Interdisciplinary Study 2023QYJC010China Postdoctoral Science Foundation 2024M753690Furong Lab Research Project 2023SK2084Major Scientific Research Project for High-level Health Talent in Hunan Province R2023047National Key R&D Program of China 2021YFA0805200National Natural Science Foundation of China 82171254National Natural Science Foundation of China 82301628National Natural Science Foundation of China 82371272National Natural Science Foundation of China 82401496Natural Science Foundation of Hunan Province 2024JJ3050Natural Science Foundation of Hunan Province 2024JJ6638Postdoctoral Fellowship Program of CPSF GZB20230870Science and Technology Innovation Program of Hunan Province 2022RC1027
6 · The paper itself

Abstract

backgroundMultiple-system atrophy is a rapidly progressive neurodegenerative disease with incomplete survival data, limiting the understanding of long-term outcomes. This study aimed to investigate a comprehensive data including survival time and prognostic factors.

methodsIndividual patient data were pooled from studies reporting Kaplan-Meier curves, and then, survival curves were generated. The pooled median survival times were derived using weighted median of medians approach and hazard ratios of risk factors were analyzed using either fixed- or random-effects model.

results37 studies involving 6145 patients were included. The median survival time for MSA patients was 8.23 years (95% CI 8.02-8.56) based on reconstructed individual patient data. The pooled weighted median time was 8.0 years (95% CI 7.51-9.0). The following variables were found as unfavorable prognostic factors (hazard ratio with 95% CI are shown): age at onset (1.02, 1.01-1.03), poor levodopa response (1.55, 1.14-2.11), parkinsonism onset (1.30, 1.05-1.62), falls (1.84, 1.4-2.4), dysautonomia onset (1.48, 1.16-1.9), autonomic failure (2.52, 1.42-4.48), orthostatism hypotension (1.39, 1.16-1.66), bladder catheterization (1.81, 1.41-2.31), and stridor (1.5, 1.12-2.02).

conclusionSurvival time in MSA was evaluated using multiple methodological approaches, revealing a median survival of 8.0 years, and clinical variables like early autonomic failure and frequently falls were identified as predictors of poor survival outcomes.

Indexed as

Multiple System AtrophyHumansPrognosisMeta-analysisMultiple-system atrophyPrognostic factorsSurvival time

Identifiers

PMID40533599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.